1. Introduction {#sec1-cancers-11-01912}
===============

The cytopathology of salivary glands presents major challenges due to the heterogeneity of benign and malignant neoplasms, which is reflected in the large range of World Health Organisation 2017 Classifications \[[@B1-cancers-11-01912]\]. Fine needle aspiration (FNA) of salivary gland tumours is still the favoured approach as it results in good sensitivity (83--92%) and specificity (93--100%) \[[@B2-cancers-11-01912]\]. Although the most commonly occurring neoplasms are relatively easy to identify from cytological specimens, some tumours are heterogeneous and/or share overlapping features, and are challenging to assign to specific categories. FNA is predominantly used to determine before surgery whether the lesion is neoplastic or not, whether the neoplasm is benign or malignant, and to differentiate between an epithelial neoplasm and a lymphoma or between a primary neoplasm and a metastasis. The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was published in 2018 and was drawn up by the American Society of Cytology and the International Academy of Cytology \[[@B3-cancers-11-01912]\]. It standardises terminology and stratified salivary gland lesions into seven categories: non-diagnostic (ND), non-neoplastic (NN), atypia of undetermined significance (AUS), benign neoplasm (BN), salivary gland neoplasm of uncertain malignant potential (SUMP), suspicious for malignancy (SM) and malignant (M). Even if the MSRSGC classification does not require a precise identification of the neoplasm, however it should be indicated whenever feasible mostly for BN and M categories. In M category, it is recommended to specify if the malignancy is either low-grade (LG-M) or high-grade (HG-M) as the malignancy grade is clinically relevant in order to plan extension of the surgical treatment. The MSRSGC has shown an accuracy of 0.67 for HG-M \[[@B4-cancers-11-01912]\] which can be improved when associated with clinically or pathologically substantiated cervical metastases (0.77). Moreover, the precise cytological identification of a neoplasm helps to determine whether it is benign or LG-M. This is not always possible based on morphology alone and in some cases, ancillary studies may be required to establish a definitive cytological diagnosis. The latter are described in the MSRSGC and predominantly include immunocytochemistry (ICC) and fluorescence in situ hybridisation (FISH). Indeed, some tumours contain specific translocations, which can be easily identified from cytological specimens \[[@B5-cancers-11-01912]\]. We report findings from a 4-year retrospective analysis of salivary gland FNA, which were reviewed and classified according to the MSRSGC. We also assess the risk of neoplasm (RON) and of malignancy (ROM) and the contribution of ancillary studies to the definitive diagnosis.

2. Results {#sec2-cancers-11-01912}
==========

2.1. Classification of Salivary Gland Cytology Using the Milan System for Reporting Salivary Gland Cytopathology {#sec2dot1-cancers-11-01912}
----------------------------------------------------------------------------------------------------------------

Between February 2014 and March 2018, 328 salivary gland FNAs from 314 patients were analysed in our laboratory. Fourteen cases originated from accessory salivary glands (4%), 291 (89%) from the parotid and 23 (7%) from the sub-mandibular glands. The median age of patients was 64 years (range 11--93) and the male/female ratio 1.17.

We received the majority of FNAs as air-dried smears with a median of 4 slides and a mean of 3.71 ± 1.87 slides per case. In 37 cases (11.28%) a liquid based cytology (LBC) was also associated. Only 3 cases were addressed in LBC alone.

Results were reviewed and classified using the MSRSGC ([Table 1](#cancers-11-01912-t001){ref-type="table"}). The most frequent diagnosis was BN (44.2%) with a majority of pleomorphic adenoma (PA) diagnoses (27,1%) ([Figure 1](#cancers-11-01912-f001){ref-type="fig"}). Moreover, 55 (16,8%) Warthin's tumours and 1 (0,3%) schwanomma were also included in the BN category. The ND category represented 25.6% of cases. We were unable to formulate a diagnosis in 84 cases (ND category) mainly due to cystic content or because of pauci-cellularity of the sample (25 (7.6%) and 55 (16.8%) cases respectively). The four last cases only contained a few lymphocytes without any epithelial cells and were thus classified as ND. About 8% of cases were reported to be NN. Most of these cases were reactive lymph nodes with inflammatory cells (12/27 cases, 44%). Normal lymph nodes (seven cases), cysts (seven cases) and sialadenitis with lithiasis (1 case) were the three other cytological diagnoses described in NN category. Malignant lesions (primary as well as secondary) represented 11.3% of cases, among these 2.7% were LG-M, 62.2% were HG-M and 35.1% were solid tumour metastases. Almost 5% of cases were reported to be SM. They were predominantly cases of suspected lymphomas (10 cases; 62.5%). SUMP represented almost 5% of the cases. As described previously, SUMP with oncocytic cells or without any specific morphological features were separated into oncocytic subtype (7/15) or unspecified subtype (8/15), respectively \[[@B6-cancers-11-01912]\]. No SUMP case with basaloid cells or basaloid features was described in our study. Finally, only 1.2% of the cases were reported in AUS category.

2.2. Correlation of Cytological Results with Histology {#sec2dot2-cancers-11-01912}
------------------------------------------------------

Post-surgery histopathological analyses were available for 216 cases (65.9%) ([Table 1](#cancers-11-01912-t001){ref-type="table"}). The majority of BN were confirmed after surgery (100% of Warthin's tumours and 94.4% of PA). Among cases classified as NN on cytopathological analysis, only one was categorised as a benign neoplasm (Warthin's tumour) after histological examination. Among the four cases classified as AUS, only two of these had surgery with histopathological analyses. Both of these cases were definitively diagnosed as benign neoplasms (one PA and one cystadenoma). Regarding the SUMP category, 7/15 corresponded to cytological cases with oncytic features among which two were finally diagnosed as oncocytic hyperplasia, one as oncocytic PA, and one as a high-grade salivary duct carcinoma. The eight remaining cases corresponded to cytological cases with unspecificied features among which four were malignant (one polymorphous low-grade adenocarcinoma, one secretory carcinomas, one adenoid cystic carcinoma and one poorly differentiated tumour ([Figure 2](#cancers-11-01912-f002){ref-type="fig"}) and four cases were non-malignant (one Warthin's tumour, one fibrous nodule, one benign cyst and one atrophic sialadenitis). The SM category was separated into suspicious for lymphoma (10/16) or suspicious for solid tumour (6/16). The diagnostic of lymphoma was confirmed in 8/10 cases. One case corresponded to a reactive lymphocytic infiltration of the parotid gland and the last case corresponded to a lymphoepithelial cyst in a HIV+ patient (we were blind of the clinical data for the cytological analysis). Among SM cases suspicious for solid tumours, 3/6 corresponded to malignant tumours (one mucoepidermoid carcinoma, one myoepithelial carcinoma and one salivary duct adenocarcinoma) and 3/6 corresponded either to PA (2/3) or a myofibroblastic granuloma. All malignant neoplasms were confirmed after surgery. The RON and the ROM for each category are indicated in [Table 1](#cancers-11-01912-t001){ref-type="table"}.

2.3. Ancillary Studies Help to Further Characterise Salivary Gland Tumours {#sec2dot3-cancers-11-01912}
--------------------------------------------------------------------------

ICC or FISH was performed in 76 and 48 cases, respectively. Results are shown in [Table 2](#cancers-11-01912-t002){ref-type="table"}. ICC was performed predominantly on smears (74/76 cases). Only two cases provided enough material to perform a cellblock used for ICC. The ICC did not contribute to the diagnosis in 27.6% of cases, due to lack of material, technical problems or due to the incorrect choice of antibody to confirm the definitive diagnosis (particularly when not enough slides were available for the analysis). In nine cases (11.8%), the ICC helped to eliminate the diagnosis of a metastasis. This is particularly useful in cases previously diagnosed with a primary tumour. In fact, as shown in [Table 3](#cancers-11-01912-t003){ref-type="table"}, among these nine cases, a medical history of neoplasm was known in three cases. The choice of antibodies used was thus defined accurately. For the six other cases, we used antibodies to eliminate a metastasis of a carcinoma (anti-AE1/AE3 antibody) or of thyroid or lung carcinoma (anti-TTF1 antibody). In 36.8% of cases, ICC helped to differentiate a BN or LG-M lesion from a HG-M lesion, predominantly with the anti-Ki67 antibody. In 18 cases (23.7%), ICC confirmed the diagnosis ([Figure 3](#cancers-11-01912-f003){ref-type="fig"} and [Figure 4](#cancers-11-01912-f004){ref-type="fig"}). Among the 13 malignant lesions diagnosed as metastasis of solid tumours, information about a primary tumour was known in 10 cases and ICC was performed in 5/10 cases. In 4/5 cases ICC provided the diagnostic. In the last case, ICC did not contribute to diagnosis due to lack of tumour cells on the slide.

FISH was always performed on smears as previously described \[[@B5-cancers-11-01912]\]. It did not contribute to the definitive diagnosis in 21% of cases (due to the interference of background staining or insufficient material). FISH was uninformative in 46% of cases, due to negative results. It provided the definitive cytological diagnosis in 33% of cases. FISH was particularly helpful for diagnosing malignant tumours (mucoepidermoid carcinoma with a *MECT1-MAML2* fusion, adenoid cystic carcinoma with a *MYB* translocation and secretory carcinoma with an *ETV6* translocation) ([Figure 5](#cancers-11-01912-f005){ref-type="fig"}).

In 11 cases, we received enough slides to perform both ICC and FISH ([Table 4](#cancers-11-01912-t004){ref-type="table"}). Six of them were BN cases (all PA), one was a SUMP case and four were M cases (one low-grade and three high-grade). When FISH is negative, ICC may help at least to differentiate BN/LG-M from HG-M using anti-Ki67 antibody and sometimes may provide the diagnosis, especially in metastasis.

3. Discussion {#sec3-cancers-11-01912}
=============

In this study, we retrospectively classified all cases of salivary gland fine needle aspirations analysed in our laboratory between 2014 and March 2018, according to the MSRSGC. A high proportion (25.6%) of cases were considered ND. This is somewhat higher than that reported in other studies by Park et al., (9.9%), Rohilla et al., (2.2%), Savant et al., (9.2%), Song et al., (13.5%), Viswanathan et al., (12%) and Wei et al., (2%) \[[@B4-cancers-11-01912],[@B7-cancers-11-01912],[@B8-cancers-11-01912],[@B9-cancers-11-01912],[@B10-cancers-11-01912],[@B11-cancers-11-01912]\]. This may be related to the method of sample collection. Indeed, most of the samples from our institution were collected at the initial patient consultation, during which the clinician performed the FNA without ultrasound-guidance. In fact, we previously showed, as did others, that ultrasound guided FNA increases the quality of the sample collected when compared to FNA performed in the absence of ultrasound guidance \[[@B12-cancers-11-01912],[@B13-cancers-11-01912]\]. This may explain the high frequency of samples with cystic content and without any informative epithelial cells observed, and also why the ROM in the ND category of our study is higher than in the MSRSGC (34% vs. 25%) \[[@B3-cancers-11-01912]\]. We also note that 4/84 samples from ND cases only contained few lymphocytes and turned out to be lymphomas. In these cases, the number of lymphocytes was too low or the cells were insufficiently preserved to provide the diagnosis.

The NN category represented 8.2% of cases. Most non-neoplastic lesions are clinically evident and the FNA is not systematically performed in these cases. In our study, 9 cases included in the NN category were analysed by histopathology with none of these cases finally diagnosed as malignant. The AUS category only comprised four samples, with only two of these undergoing surgery and therefore histopathological analysis. Both cases were finally diagnosed as benign neoplasms (one PA and one cystadenoma) and the ROM cannot be interpreted for this category. The majority of our cases were classified as BN. Indeed, PA and Warthin's tumours were the most frequent diagnoses (respectively 27.1% and 16.8% of total cases). This is consistent with the frequency reported in the literature \[[@B9-cancers-11-01912],[@B10-cancers-11-01912],[@B14-cancers-11-01912],[@B15-cancers-11-01912]\]. These diagnoses are indeed straightforward for representative samples. However, four cases of PA identified on cytological samples turned out to be malignant after pathological examination. Among these four cases, three of them turned out to be carcinomas ex PA. These lesions can be difficult to detect on cytological samples due to the absence of the carcinoma component in the FNA. The last false negative PA case turned out to be an adenoid cystic carcinoma. In fact, adenoid cystic carcinoma is one of the differential diagnosis when highly cellular FNA sample is observed with scant matrix, which was the case here \[[@B3-cancers-11-01912]\]. Regarding the SUMP category, it represents only 4.6% of the cases and half of them was composed of cells with oncocytic features. Two of the oncocytic SUMP cases were finally diagnosed as neoplasm (1/4 benign and 1/4 malignant) after pathological examination. The two other oncoyctic SUMP cases were non neoplastic lesions (oncocytic hyperplasia). Among the eight unspecified SUMP cases, four turned out to be malignant neoplasm, one benign neoplasm and two non-neoplastic after pathological examination. One of these two non-neoplastic lesions was an atrophic sialadenitis which is one of the pitfalls of FNA cytological examination since ICC is not contributive in these cases \[[@B6-cancers-11-01912]\]. The other non-neoplastic lesion was a fibrous nodule. Numerous fibroblasts were present in this lesion and these cells have been confused with atypical cells on cytological smears. The RON and ROM for SUMP category, oncocytic SUMP subtype and unspecified SUMP subtype are consistent with the MSRSGC and previous studies \[[@B3-cancers-11-01912],[@B6-cancers-11-01912],[@B14-cancers-11-01912],[@B15-cancers-11-01912]\]. The SM category was also seldom used since it represented only 4.9% of our cases. Among the 16 SM cases, five cases were not malignant after histological analysis. Two of the cases suspicious for lymphoma turned out to be non-neoplastic (one reactive lymph node and one lymphoepithelial cyst). The three other cases which were suspicious for epithelial malignancy were finally diagnosed as non-neoplastic (myofibroblastic granuloma) or benign neoplasm (two PA). Though, the ROM for SM is consistent with the MSRSGC (68.8% vs. 60%) and with the literature (68,8% vs. 79%, 59%, 58%) \[[@B9-cancers-11-01912],[@B11-cancers-11-01912],[@B16-cancers-11-01912]\].

As most of the samples were provided as smears, we systematically stained the slides which contained the most cells with May-Grünwald-Giemsa (MGG). This allows good differentiation between the cells and the matrix, which is particularly useful for visualising matrix-rich tumours such as PA, adenoid cystic carcinomas and basal cell adenomas. Both MGG and Papanicolaou stain the mucus present in mucoepidermoid carcinomas. We observed that oncocytic cells present in Warthin's tumours displayed characteristic orange-stained cytoplasms with Papanicolaou. When the lesion was evident, we stained the remaining slides either with MGG or with others stains. When the nature of the tumour was not evident, ICC or FISH analyses were performed on the remaining slides, as suggested by Jo et al., who reported a useful algorithm for the use of ancillary tests \[[@B17-cancers-11-01912]\]. ICC was informative in 72.4% of cases. It was used to eliminate a metastasis in 11.8% of cases, discarding lung adenocarcinoma or thyroid carcinoma (TTF1-), epidermoid carcinoma (p63-), and melanoma (pS100, MelanA, HMB45). However, for some tumours such as squamous cell carcinoma, adenocarcinoma, and neuroendocrine small cell carcinoma, it is sometimes difficult to determine whether the tumour originated from the salivary gland or whether it is an intra-glandular lymph node metastasis. The clinical data is of special interest in these cases. ICC helped to differentiate BN/LG-M lesion from HG-M neoplasms in 36.8% of cases and provided the definitive diagnosis in 23.7% of cases (either by negative pancytokeratin staining indicating the absence of epithelial cells, the presence of mixed B and T reactive lymphocytes or the low percentage (\<5%) of Ki67 positive cells). It was not informative in 27.6% of cases predominantly due to the presence of insufficient cells on the remaining slides available for analysis.

Our study used a limited panel of antibodies which could be extended to include EpCAM and LEF-1 for example. EpCAM expression has been shown in 97.6% of adenoid cystic carcinomas and its intensity is correlated with a poor prognosis but it cannot be used for a differential diagnosis on cytological samples \[[@B18-cancers-11-01912]\]. LEF-1 has been shown to be positive in benign basaloid neoplasm tests \[[@B19-cancers-11-01912]\]. Griffith et al., have developed a user-friendly pattern approach for the sequential use of ancillary tests \[[@B20-cancers-11-01912]\]. According to the staining patterns obtained, a combination of immunostains useful for any subsequent characterisation is proposed. However, the limitation of the Griffith et al., approach is the limiting quantity of remaining sample which is available for analysis. ICC is more robust when performed on cellblocks, which necessitate sufficient amounts of material.

We observed that 13/37 salivary gland lesions identified as malignant were indeed metastases. It is generally difficult to differentiate between a primary and a secondary lesion. Indeed, in a recent review, Pastore et al., reported that 71% of salivary gland metastases in their institution arose from cutaneous head and neck tumours, 12% from the upper digestive tract, 12% from locations out of cervical region and 5% remained from unknown origin \[[@B21-cancers-11-01912]\]. Wang et al., showed that metastatic squamous cell carcinoma from all sites (47.3%) and melanoma (36.4%) constituted the majority of secondary malignancies of salivary glands \[[@B22-cancers-11-01912]\]. This is very similar to our observations, as 13 metastatic lesions in our study were identified as metastasis on cytology while 4/23 HG-M turned out to be metastasis on the pathological examination. Overall, 7/17 of the metastatic lesions originated from head and neck tumours, 5/17 from lung tumours (4 adenocarcinomas, 1 small cell carcinomas), 1/17 from urothelial carcinoma, 1/17 from Merckel cell carcinoma, 1/17 from melanoma and for 2/17 we were unable to identify the origin of the primary tumour. The presence of lymphocytes admixed with cancer cells is usually suggestive of a metastasis. However, the clinical history is the most informative indicator as it guides the choice of the most appropriate ICC tests to perform.

FISH analysis provided a definitive diagnosis in 33.3% of cases. It is very useful to definitively identify some tumours such as adenoid cystic carcinomas, secretory carcinomas, mucoepidermoid carcinomas and PA when they display unusual features. As the matrix is auto-fluorescent, FISH can be difficult to interpret when the matrix is very abundant. In such cases, it can only be interpreted when the actual diagnostic sample is positive. As we have already shown, the very high specificity of FISH allowed us to establish definitive diagnoses specifically in cases of adenoid cystic carcinomas, secretory carcinomas and mucoepidermoid carcinomas \[[@B5-cancers-11-01912]\]. It is less useful for PA due to their easier cytological identification and because *PLAG1* gene rearrangement is present in only 60% of cases and because it does not differentiate benign from malignant forms. Using ICC and/or FISH analysis, the ROM for the M category was determined to be 100%. Park et al., observed a similar risk for this category, in accordance with the MSRSGC \[[@B4-cancers-11-01912]\].

4. Materials and Methods {#sec4-cancers-11-01912}
========================

4.1. Cytological Samples {#sec4dot1-cancers-11-01912}
------------------------

From February 2014 to March 2018, 328 salivary gland FNAs from 314 patients were received by our laboratory. The FNAs were performed using a 25-gauge needle. The clinician collected most of the samples when the patient consulted for an enlargement of a salivary gland. In some cases, a radiologist performed the puncture under guided ultrasound. Samples were received by the laboratory predominantly as air-dried smears, and/or sometimes as liquid based cytology (Hologic). For smears, one slide was systematically stained with May-Grünwald-Giemsa (MGG) in order to establish a diagnosis. If the diagnosis could be established, the remaining slides were stained with MGG or if necessary with Papanicolaou, Periodic Acid-Schiff (PAS) or Alcian blue. If the diagnosis was not evident, the remaining slides were used for ICC and/or FISH.

4.2. Cytological Classification {#sec4dot2-cancers-11-01912}
-------------------------------

The cytological diagnoses were reviewed and retrospectively classified using the MSRSGC. They were classified as follows: non-diagnostic (ND), non-neoplastic (NN), atypia of undetermined significance (AUS), benign neoplasm (BN), salivary gland neoplasm of uncertain malignant potential (SUMP), suspicious for malignancy (SM) and malignant (M). For each diagnosis, we reported whether ICC and/or FISH was performed. The risk of neoplasm (RON) and the risk of malignancy (ROM) were calculated according to the definitive pathological diagnosis for all cytological categories.

4.3. Immunocytochemistry {#sec4dot3-cancers-11-01912}
------------------------

Immunocytochemistry (ICC) analyses using different antibodies (listed in [Table 5](#cancers-11-01912-t005){ref-type="table"}) were performed on the Dako Autostainer system or the Ventana Benchmark automated staining system according to the manufacturers' recommendations. A polymer linked to a peroxidase system with DAB was used to amplify and visualize the signal. ICC results were classified as being either not contributing for the diagnosis, eliminating metastases of secondary tumours, differentiating Benign/LG-M from HG-M or providing the definitive diagnosis.

4.4. FISH {#sec4dot4-cancers-11-01912}
---------

The FISH probes used in our laboratory as well as the FISH procedure have been described previously \[[@B5-cancers-11-01912]\]. The result of FISH was classified as either not contributing to the diagnosis (because of a negative result), not helpful (negative) or providing the definitive diagnosis.

4.5. Histopathological Results Classification {#sec4dot5-cancers-11-01912}
---------------------------------------------

When available, histopathological results were correlated with cytology for all of the categories. Histopathological results were separated into non-neoplastic, benign neoplasm or malignant.

5. Conclusions {#sec5-cancers-11-01912}
==============

In conclusion, the MSRSGC is more effective when specific features of neoplasms can be identified. Ancillary studies help to further characterise salivary gland tumours and thereby increase the accuracy of MSRSGC.
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![Benign neoplasm: a typical pleomorphic adenoma with plasmacytoid cells mixed with a fibrillary matrix which stains magenta on MGG, (scale bar: 100 µm).](cancers-11-01912-g001){#cancers-11-01912-f001}

![Example of one case classified as SUMP with unspecified features after cytological analysis and diagnosed as poorly differentiated carcinoma after surgery. On this picture, we can see a cluster of atypical cells with high nuclear/cytoplasmic ratio which is close to a fibrillary matrix (MGG staining). FISH with *PLAG1* or *MYB* probes were negative, (scale bar: 100 µm).](cancers-11-01912-g002){#cancers-11-01912-f002}

![Malignant tumour: Secretory carcinoma. (**a**) On Papanicolaou staining we observed a high cellular content, papillary structures and the presence of cells with foamy cytoplasm, (scale bar: 500 µm); (**b**) ICC performed on smears revealed that cells were positive for mammaglobin, (scale bar: 100 µm).](cancers-11-01912-g003){#cancers-11-01912-f003}

![Malignant tumour: metastasis from lung adenocarcinoma (**a**) The cells had high N/C ratio but did not show any specific differentiation (MGG staining; scale bar: 100 µm); (**b**) ICC performed on a cellblock revealed that cells were positive for TTF1 (scale bar: 200 µm).](cancers-11-01912-g004){#cancers-11-01912-f004}

![Malignant tumour: adenoid cystic carcinoma: (**a**) On the MGG staining, we observed the typical tubular and hyaline globules, (scale bar: 500 µm); (**b**) FISH performed on the same case revealed rearrangement of the *MYB* gene as indicated by a split between the green and red signal, (scale bar: 40 µm).](cancers-11-01912-g005){#cancers-11-01912-f005}

cancers-11-01912-t001_Table 1

###### 

Classification of cytological results and correlation with histological results. *RON: risk of neoplasm; ROM: risk of malignancy.*

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cytopathology                                                     Histopathology        RON         ROM                                                                                                          
  ----------------------------------------------------------------- --------------------- ----------- ----------- ------------ ---------- ------------- ------------- -------------- --------------- ------------- --------------
  Non-Diagnostic (ND)                                               Pauci-cellular        55 (16.8)   84\         24           2          20            9             29/31 (93.5)   38/47\          9/31 (29)     16/47 (34)
                                                                                                      (25.6)                                                                         (80.9)                        

  Cystic content                                                    25 (7.6)              13          3           6            3          9/12 (75)     3/12 (25)                                                  

  Lymphocytes                                                       4 (1.2)               \-          \-          \-           4          4/4 (100)     4/4 (100)                                                  

  Non-Neoplastic (NN)                                               Normal lymph node     7 (2.1)     27 (8.2)    5            2          \-            \-            0/9 (0)        1/9 (11.1)      0/9 (0)       0/9 (0)

  Reactive lymph node/Inflammation                                  12 (3.7)              10          2           \-           \-         0/9 (0)       0/9 (0)                                                    

  Lithiasis/sialadenitis                                            1 (0.3)               1           \-          \-           \-         0/9 (0)       0/9 (0)                                                    

  Cyst                                                              7 (2.1)               2           4           1            \-         1/9 (11.1)    0/9 (0)                                                    

  Atypia of Undetermined Significance (AUS)                         4 (1.2)               4 (1.2)     2           \-           2          \-            2/2 (100)     2/2 (100)      0/2 (0)         0/2 (0)       

  Benign Neoplasm (BN)                                              Pleomorphic adenoma   89 (27.1)   145\        18           \-         67            4             71/71 (100)    105/105 (100)   4/71 (5.63)   4/105 (3.09)
                                                                                                      (44.2)                                                                                                       

  Warthin's tumour                                                  55 (16.8)             21          \-          34           \-         34/34 (100)   0/34 (0)                                                   

  Schwanomma                                                        1 (0.3)               1           \-          \-           \-         \-            \-                                                         

  Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP)   Oncocytic             7 (2.1)     15 (4.6)    3            2          1             1             2/4 (50)       7/11 (63.6)     1/4 (25)      5/11 (45.5)

  Unspecified                                                       8 (2.4)               1           2           1            4          5/7 (71.4)    4/7 (57.1)                                                 

  Suspicious for malignancy (SM)                                    Epithelial            6 (1.8)     16 (4.9)                 1          2             3             5/6 (83.3)     13/16 (81.3)    3/6 (50)      11/16\
                                                                                                                                                                                                                   (68.8)

  Lymphoma                                                          10 (3.1)              \-          2           \-           8          8/10 (80)     8/10 (80)                                                  

  Malignant (M)                                                     Low-grade             1 (0.3)     37\         \-           \-         \-            1             1/1 (100)      26/26 (100)     1/1 (100)     26/26\
                                                                                                      (11.3)                                                                                                       (100)

  High-grade                                                        23 (7)                4           \-          \-           19         19/19 (100)   19/19 (100)                                                

  Metastasis                                                        13 (4)                7           \-          \-           6          6/6 (100)     6/6 (100)                                                  

  Total                                                                                   328 (100)   328 (100)   112 (34.2)   18 (5.5)   136 (41.5)    62 (18.9)     \-                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cancers-11-01912-t002_Table 2

###### 

Contributions of immunocytochemistry and FISH to the definitive diagnosis. ICC: Immunocytochemistry; LN: lymph node; LG-M: Low-grade malignant; HG-M: High-grade malignant.

  Cytopathology                                                     Immunocytochemistry   FISH                                                                                                                                                                                 
  ----------------------------------------------------------------- --------------------- -------------------- ------------------- ------------------ ------------------- ------------------- -------------------- ------------------- ------------------- ------------------- ------------
  Non-Diagnostic (ND)                                               Pauci-cellular        55                   **2/55 (3.6%)**     1 (50%)                                1 (50%)                                                                                              
  Cyst content                                                      25                    **3/25 (12%)**       1 (33.3%)           1 (33.33%)         1 (33.3%)                               **1/25 (4%)**                            1 (100%)                                
  Lymphocytes                                                       4                     **3/4 (75%)**        2 (66.7%)                                                  1 (33.3%)                                                                                            
  Non-Neoplastic (NN)                                               Normal LN             7                    **3/7 (42,9%)**                        3 (100%)                                                                                                                 
  Inflammation                                                      12                    **6/12 (50%)**                           1 (16,7%)          5 (83,3%)                                                                                                                
  Sialadenitis                                                      1                     **1/1 (100%)**                                              1 (100%)                                                                                                                 
  Cyst                                                              7                     **1/7 (14.3%)**                                                                 1 (100%)                                                                                             
  Atypia of undetermined significance (AUS)                         4                     **3/4 (75%)**        3 (100%)                                                                       **1/4 (25%)**        1 (100%)                                                    
  Benign neoplasm (BN)                                              Pleomorphic adenoma   89                   **12/89 (13.5%)**   2 (16.7%)                              9 (75%)             1 (8.3%)             **32/89 (36%)**     7 (21.9%)           14 (43.8%)          11 (34.4%)
  Warthin's tumour                                                  55                    **1/55 (1.8%)**                                             1 (100%)                                **1/55 (1.82%)**                         1 (100%)                                
  Other                                                             1                                                                                                                                                                                                          
  Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP)   Oncocytic             7                    **3/7 (42.9%)**     2 (66.7%)                              1 (33.3%)                                **3/7 (42.9%)**     1 (33.3%)           2 (66.7%)           
  Undetermined                                                      8                     **2/8 (25%)**        1 (50%)                                1 (50%)                                 **3/8 (37.5%)**      1 (33.3%)           1 (33.3%)           1 (33.3%)           
  Suspicious for malignancy (SM)                                    Epithelial            6                    **3/6 (50%)**       3 (100%)                                                                        **3/6 (50%)**                           2 (66.7%)           1 (33.3%)
  Lymphoma                                                          10                    **7/10 (70%)**       2 (28.6%)           2 (28.6%)          1 (14.3%)           2 (28.6%)                                                                                            
  Malignant (M)                                                     Low-grade             1                    **1/1 (100%)**                                                                 1 (100%)             **1/1 (100%)**                                              1 (100%)
  High-grade                                                        23                    **17/23 (73.9%)**    3 (17.6%)           2 (11.8%)          6 (35.3%)           6 (35.3%)           **2/23 (8.7%)**                                              2 (100%)            
  Metastasis                                                        13                    **8/13 (61.5%)**     2 (25%)                                1 (12.5%)           5 (62.5%)                                                                                            
  Total                                                             **328**               **76/328 (23,2%)**   **21/76 (27.6%)**   **9/76 (11.8%)**   **28/76 (36.8%)**   **18/76 (23.7%)**   **48/328 (14.6%)**   **10/48 (20.8%)**   **22/48 (45.8%)**   **16/48 (33.3%)**   
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###### 

Details of the nine cases in which ICC allowed to eliminate a metastasis. ND: Non-Diagnostic; NN: Non-Neoplastic; SM: Suspicious for Malignancy; M: Malignant; HG: High-grade; neg: negative; pos: positive; DLBCL: Diffuse large B-cell lymphoma; GC: germinal center.

  Patient   Medical History of Neoplasm                               Milan System Category   Cytological Diagnosis        Immunochemistry   Histological Diagnosis                                                                                   
  --------- --------------------------------------------------------- ----------------------- ---------------------------- ----------------- ------------------------ ------------------------------------------------------------------------------- --------------------------------
  58        None                                                      ND                      Cyst content                 TTF1              neg                      eliminated metastasis of potential papillary thyroid carcinoma                  Mucoepidermoid carcinoma ex PA
  85        Tongue squamous cell carcinoma diagnosed 1 month before   NN                      reactive lymph node          AE1/AE3           neg                      eliminated metastasis of the squamous cell carcinoma previously diagnosed       not performed
  CD3       pos                                                                                                                                                                                                                                       
  CD20      pos                                                                                                                                                                                                                                       
  86        Metastatic lung adenocarcinoma diagnosed 3 month before   NN                      normal lymph node            AE1/AE3           neg                      eliminated metastasis of the lung adenocarcinoma previously diagnosed           not performed
  CD3       pos                                                                                                                                                                                                                                       
  CD20      pos                                                                                                                                                                                                                                       
  CK7       neg                                                                                                                                                                                                                                       
  TTF1      neg                                                                                                                                                                                                                                       
  93        None                                                      NN                      normal lymph node            CD3               pos                      eliminated metastasis of a carcinoma                                            not performed
  CD20      pos                                                                                                                                                                                                                                       
  CK7       neg                                                                                                                                                                                                                                       
  94        Papillary thyroid carcinoma diagnosed in 1996             NN                      normal lymph node            TTF1              neg                      eliminated metastasis of the papillary thyroid carcinoma previously diagnosed   Normal lymph node
  284       None                                                      SM                      lymphoma                     AE1/AE3           neg                      eliminated metastasis of a carcinoma                                            Follicular lymphoma grade 1--2
  285       None                                                      SM                      lymphoma                     AE1/AE3           neg                      eliminated metastasis of a carcinoma                                            DLBCL non-GC
  297       None                                                      M (HG)                  undifferenciated carcinoma   TTF1              neg                      eliminated metastasis of a lung adenocarcinoma                                  salivary duct carcinoma
  p63       pos                                                                                                                                                                                                                                       
  298       None                                                      M (HG)                  undifferenciated carcinoma   TTF1              neg                      eliminated metastasis of a lung adenocarcinoma                                  salivary duct carcinoma
  p63       pos                                                                                                                                                                                                                                       
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###### 

Cases with Immunocytochemistry and FISH. BN: Benign-Neoplasm; SUMP: Salivary Gland Neoplasm of Uncertain Malignant Potential; M: Malignant; LG: Low-grade HG: High-grade; PA: pleomorphic adenoma; AdCC: adenoid cystic carcinoma; SC: secretory carcinoma; ADK, NOS: adenocarcinoma not otherwise specified; neg: negative; pos: positive.

  Patient   Milan System Category   Cytological Diagnosis          Histological Diagnosis               Immunocytochemistry   FISH                                                      
  --------- ----------------------- ------------------------------ ------------------------------------ --------------------- --------- --------------------------------- ------- ----- ------------------------
  116       BN                      PA                             PA                                   Ki67                  1% pos    Eliminated HG-M                   PLAG1   neg   No help
  117       BN                      PA                             PA                                   Ki67                  2% pos    Eliminated HG-M                   PLAG1   neg   No help
  118       BN                      PA                             not performed                        p63                   pos       provided the diagnosis            PLAG1   pos   Provided the diagnosis
  119       BN                      PA                             not performed                        Ki67                  2% pos    Eliminated HG-M                   PLAG1   pos   Provided the diagnosis
  120       BN                      PA                             not performed                        Ki67                  1% pos    Eliminated HG-M                   PLAG1   pos   Provided the diagnosis
  121       BN                      PA                             PA                                   Ki67                  3% pos    Eliminated HG-M                   PLAG1   pos   Provided the diagnosis
  264       SUMP                    SUMP with Oncocytic features   Cellular PA with oncocytyc cells     Ki67                  3% pos    Eliminated HG-M                   PLAG1   neg   No help
  293       M (HG)                  AdCC                           AdCC                                 Ki67                  10% pos   In favor of HG-M                  MYB     pos   Provided the diagnosis
  PLAG1     neg                                                                                                                                                                         
  294       M (HG)                  AdCC                           AdCC                                 p63                   pos       did not contribute to diagnosis   MYB     pos   Provided the diagnosis
  295       M (LG)                  SC                             SC                                   MAM                   30% pos   provided the diagnosis            ETV6    pos   Provided the diagnosis
  299       M (HG)                  ADK, NOS                       metastasis of lung adeno-carcinoma   Ki67                  20% pos   In favor of HG-M                  ETV6    neg   No help
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###### 

Antibodies and corresponding protocols used (antigen retrieval, concentration).

                        Provider        Antigen Retrieval   Automate            Dilution
  --------------------- --------------- ------------------- ------------------- ----------
  CD3                   Roche           pH9                 Ventana, Roche      RTU
  CD79a                 Roche           pH9                 Ventana, Roche      RTU
  CD15                  Roche           pH9                 Ventana, Roche      RTU
  CD30                  Roche           pH9                 Ventana, Roche      RTU
  CD45                  Roche           pH9                 Ventana, Roche      RTU
  CD68-PGM1             Clinisciences   No                  Ventana, Roche      1/100
  CD56                  Roche           pH9                 Ventana, Roche      RTU
  AE1/AE3               Agilent         No                  Autostainer, Dako   RTU
  p63                   Agilent         pH9                 Autostainer, Dako   1/50
  p40                   Dako            pH6                 Autostainer, Dako   1/200
  CK5/6                 Agilent         No                  Autostainer, Dako   1/100
  CK7                   Agilent         No                  Autostainer, Dako   1/400
  CK20                  Agilent         No                  Autostainer, Dako   1/200
  TTF1                  Agilent         pH6                 Autostainer, Dako   RTU
  Chromogranin          Agilent         No                  Autostainer, Dako   1/100
  Synpatophysin         MM France       pH9                 Autostainer, Dako   RTU
  Ki67                  Agilent         pH6                 Autostainer, Dako   1/50
  Mammaglobin           Dako            No                  Autostainer, Dako   RTU
  Desmin                Agilent         No                  Autostainer, Dako   1/100
  Vimentin              Dako            No                  Autostainer, Dako   RTU
  Smooth Muscle Actin   Agilent         No                  Autostainer, Dako   RTU
  Androgen Receptor     Dako            pH9                 Autostainer, Dako   1/200
  MelanA                Agilent         No                  Autostainer, Dako   RTU
                        \(1\)                                                   

RTU: ready-to-use.
